ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailMenu BurgerPositive ArrowIcon PrintIcon SearchSite TitleTitle ChevronIcon Twitter
Business

Mitsui may invest in Russian drugmaker

TOKYO -- Lured by the growth prospects of Russia's pharmaceutical market, Japanese trading house Mitsui & Co. is considering investing in Moscow-based drugmaker R-Pharm.

Mitsui is expected to flesh out details by the end of the current fiscal year through March 2017. The company could spend more than 10 billion yen ($96.3 million) to take a stake of just over 10% in R-Pharm.

Mitsui has been beefing up medical-related operations, eyeing such fields as contract manufacturing of pharmaceuticals and production of generic drugs. In July, the company decided to buy into the Columbia Asia group, a major hospital operator.

In Russia, Mitsui is joining hands with the Japan Bank for International Cooperation to invest a combined 34 billion yen in state-run power company RusHydro.

Japanese Prime Minister Shinzo Abe is seeking to deepen ties with Moscow. Mitsui's R-Pharm deal could be positioned as part of economic cooperation between Japan and Russia.

(Nikkei)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends January 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media